This late benefit highlights the importance of long-term follow-up of breast cancer trials, particularly for women with hormone receptor-positive disease whose risk of recurrence persists at about the same annual rate for up to 20 years after diagnosis.17 The gene discussed is NR4A1; the disease is glycogen storage disease VI.